H. Lundbeck A/S- (OTCMKTS:HLUYY) hit a new 52-week low on Friday . The stock traded as low as $38.31 and last traded at $38.31, with a volume of 432 shares changing hands. The stock had previously closed at $38.91.
HLUYY has been the subject of several analyst reports. Zacks Investment Research raised H. Lundbeck A/S- from a “sell” rating to a “hold” rating in a report on Friday, March 1st. ValuEngine cut H. Lundbeck A/S- from a “hold” rating to a “sell” rating in a report on Thursday, April 11th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. H. Lundbeck A/S- presently has an average rating of “Hold” and an average target price of $53.00.
The firm has a market cap of $7.75 billion, a price-to-earnings ratio of 10.16, a price-to-earnings-growth ratio of 9.68 and a beta of -0.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.32 and a quick ratio of 1.08.
About H. Lundbeck A/S- (OTCMKTS:HLUYY)
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia.
Recommended Story: How is the LIBOR rate calculated?
Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.